Latest News and Events
Filter by
Selections
August 1, 2025
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Read MoreJuly 28, 2025
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
Read MoreJuly 24, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 23, 2025
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
Read MoreJuly 8, 2025
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Read MoreJune 23, 2025